SCHEMBL635334

SCHEMBL635334

COc1ccc2cc3c(=O)n(C)cc(C(=O)NCCN(C)C)c3nc2c1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAD52 P43351 5/20 0.52
UHRF1 Q96T88 1/20 0.52
SMARCA2 P51531 1/20 0.48
KDM4E B2RXH2 3/20 0.47
POLB P06746 2/20 0.42
KMT2A Q03164 5/20 0.42
GPR55 Q9Y2T6 1/20 0.42
ALDH1A1 P00352 4/20 0.41
MEN1 O00255 3/20 0.41
USP2 O75604 1/20 0.41
BRD4 O60885 1/20 0.41
RAB9A P51151 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
POLR1A O95602 2/20 0.41
ECE1 P42892 1/20 0.41
MUS81 Q96NY9 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.40
GLA P06280 1/20 0.40
PKM P14618 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL634915 0.81 RAD52 (0.54) RAD52UHRF1SMARCA2KDM4EKMT2A
SCHEMBL4106757 0.81 POLB (0.47) KDM4EPOLBKMT2AALDH1A1MEN1
SCHEMBL30122373 0.81 RAD52 (0.49) RAD52UHRF1SMARCA2KDM4EALDH1A1
SCHEMBL30122363 0.81 RAD52 (0.49) RAD52UHRF1SMARCA2KDM4EALDH1A1
SCHEMBL634092 0.81 RAD52 (0.49) RAD52UHRF1SMARCA2KDM4EALDH1A1
SCHEMBL634175 0.79 RAD52 (0.64) RAD52UHRF1SMARCA2KDM4EALDH1A1
SCHEMBL30122275 0.76 POLR1A (0.50) RAD52UHRF1KDM4EKMT2AALDH1A1
SCHEMBL29058295 0.76 POLR1A (0.50) RAD52UHRF1KDM4EKMT2AALDH1A1
SCHEMBL635769 0.76 POLR1A (0.49) RAD52UHRF1KDM4EPOLBALDH1A1
SCHEMBL634917 0.75 RAD52 (0.53) RAD52UHRF1SMARCA2POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507778-B1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES UNIV TROBE (AU) 2012-02-22 EP disclosed
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES BAGULEY BRUCE CHARLES 2009-06-18 US disclosed
US-7504507-B2 Anti-tumour polycyclic carboxamides AUCKLAND UNISERVICES LIMITED (NZ) 2009-03-17 US disclosed
US-20050245561-A1 Anti-tumour polycyclic carboxamides AUCKLAND UNISERVICES LIMITED (NZ) 2005-11-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156630-A1 ANTI-TUMOUR POLYCYCLIC CARBOXAMIDES MKI67, MCL1, CCNI RAD52 2694/4885UHRF1 1983/4885SMARCA2 1907/4885
US-20050245561-A1 Anti-tumour polycyclic carboxamides MKI67, MCL1, CCNI RAD52 2746/4885UHRF1 1913/4885SMARCA2 1655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.